COMPARISON OF QUANTITATIVE EVALUATION OF HBSAG WITH LEVELS OF VIREMIA AND ɑ-FETOPROTEIN IN PATIENTS WITH CHRONIC HBEAG-NEGATIVE VIRAL HEPATITIS B

Research objective: investigate correlation between the levels of HBsAg, hepatitis B virus (HBV) DNA and ɑ-fetoprotein in patients with diagnosis of chronic HBeAg-negative viral hepatitis B. Materials and methods: samples from 89 patients with diagnosis of chronic viral hepatitis B were studied during the first half of 2016. Laboratory assessment was performed in FBIS “Khabarovsk research institute of epidemiology and microbiology” of Rospotrebnadzor. The samples were diagnosed for the presence of HBV DNA, serological markers of hepatitis B (qualitative and quantitative evaluation of HBsAg, antibodies to HBcAg, Ig M antibodies to HBcAg, HBeAg and antibodies to HBeAg); antibodies to hepatitis D and quantitative evaluation of ɑ-fetoprotein Results and discussion: after conducting correlation analysis between levels of HBsAg and HBV DNA in blood serum of patients with diagnosis of chronic HBeAg-negative viral hepatitis B were obtained mixed results. The research revealed negative correlation between HBsAg and ɑ-fetoprotein levels. Conclusion: quantitative evaluation of HBsAg in blood serum of patients with diagnosis of chronic HBeAg-negative viral hepatitis B is not informative for estimation of level of HBV DNA. Further study is needed in order to confirm received data on negative correlation between HBsAg and ɑ-fetoprotein levels in order to investigate their interference.

хронический вирусный гепатит В, количественное определение HBsAg, ДНК вируса гепатита В, альфа фетопротеин, chronic viral hepatitis B, quantitative evaluation of HBsAg, hepatitis B DNA, alfa fetoprotein

1. Дудина К.Р., Знойко О.О., Шутько С.А. и др. Динамическое определение количественного содержания HBsAg в крови в сопоставлении с уровнем вирусной нагрузки у пациентов с хронической HBV-моноинфекцией // Гепатология. - 2011. - № 4. - С. 37-42.

2. Зайцев И.А. Использование количественного определения HBsAg для мониторинга естественного течения хронической HBV-инфекции // Гастроэнтерология. - 2015. - № 3 (57).- С.107-115.

3. Майер К.-П. Гепатит и последствия гепатита: Практич. рук.: Пер. с нем. - 2-е изд., перераб. и доп. - М.: ГЕОТАР-МЕД, 2004. - 720с.

4. Эпидемиологический надзор за гепатитом В: Методические указания. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2011. - 47 с.

5. Akuta N,Suzuki F,Kobayashi M et all. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis // J Med Virol.2014 Jan. - Vol.86(1) - P.131-8. doi: 10.1002/jmv.23790. Epub 2013 Oct 12.

6. Ben Slama N, Ahmed SN, Zoulim F. HBsAg quantification: virological significance // Gastroenterol Clin Biol. - 2010 Sep. - Vol.34, Suppl 2-S112-8. doi: 10.1016/S0399-8320(10)70030-0.

7. Fujiko M, Chalid MT, Turyadi et all. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction? // Int J Infect Dis. - 2015 Dec. Vol.41/ - P. 83-9. doi: 10.1016/j.ijid.2015.11.002. Epub 2015 Nov 10.

8. Gervain J. Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening // Orv Hetil. - 2010 Aug 29. Vol.151(35). - P.1415-7. doi: 10.1556/OH.2010.28945.

9. Jung Min Lee and Sang Hoon Ahn. Quantification of HBsAg: Basic virology for.clinical practice //World J Gastroenterol. - 2011 Jan 21- Vol. 17(3).- P.283-289.

10. Kreczko S, Lipska AWysocka J. Alpha-fetoprotein: diagnostic value in hepatic disorders // Pol Merkur Lekarski. - 2000 Jun. - Vol.8(48). -P.420-3.

11. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients // Liver Int. - 2015 Jan. - Vol.35, Suppl 1. - P.82-90. doi: 10.1111/liv.12735.

12. Rodríguez M, González-Diéguez ML. Quantification of the hepatitis B surface antigen in the characterization and follow-up // Gastroenterol Hepatol. - 2014 Jul. - P.37 Suppl 2:8-14. doi: 10.1016/S0210-5705(14)70063-9.

13. Viganò M, Lampertico P. Clinical implications of HBsAg quantification in patients with chronic hepatitis B // Saudi J Gastroenterol. - 2012 Mar-Apr. - Vol.18(2). - P.81-6. doi: 10.4103/1319-3767.93805.

14. Wiegand J., Wedemeyer H., Finger A. et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels // Antivir. Ther. - 2008. - Vol.13. - P. 547-554.

15. Yang Y, Gao J, Li HL et all. Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women // Int J Cancer.- 2016 Jul 15. - Vol.139(2). - P. 355-62. doi: 10.1002/ijc.30086. Epub 2016 Mar 30.